Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupFRA:MX6A -0.98%88 Debt-to-EBITDA is 10.35 as of Dec. 2025, which is 661% above its 10-year median of 1.36. GuruFocus rates FRA:MX6A with a GF Score™ of 88/100 and a GF Value™ of €0.63 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 675 Drug Manufacturers companies, Grand Pharmaceutical Group ranks worse than 66.07% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Grand Pharmaceutical Group's Debt-to-EBITDA or its related term are showing as below:
FRA:MX6A'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.97 Med: 1.36 Max: 4.04
Current: 2.85
During the past 13 years, the highest Debt-to-EBITDA Ratio of Grand Pharmaceutical Group was 4.04. The lowest was 0.97. And the median was 1.36.
FRA:MX6A's Debt-to-EBITDA is ranked worse than 66.07% of 675
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs FRA:MX6A: 2.85
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Grand Pharmaceutical Group Debt-to-EBITDA Related Terms
Grand Pharmaceutical Group Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Grand Pharmaceutical Group (FRA:MX6A) has a Debt-to-EBITDA of 10.35 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Grand Pharmaceutical Group. This is 661% above median its historical median of 1.36. Over the past decade, Grand Pharmaceutical Group's Debt-to-EBITDA has ranged from 0.97 to 4.04. According to the industry distribution chart, Grand Pharmaceutical Group ranks #446 out of 675 companies in the Drug Manufacturers industry, placing it in the top 66.1%.
Is Grand Pharmaceutical Group's Debt-to-EBITDA too high?
Grand Pharmaceutical Group's current Debt-to-EBITDA of 10.35 is 661% above median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 4.04. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Grand Pharmaceutical Group's value of 10.35 is 531.1% above this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #446 out of 675 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #446 out of 675 companies for Debt-to-EBITDA. This places Grand Pharmaceutical Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Grand Pharmaceutical Group's value of 10.35 is 531.1% above this benchmark. Historically, Grand Pharmaceutical Group's own Debt-to-EBITDA has ranged from 0.97 to 4.04 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 1.64, Grand Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 675 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Debt-to-EBITDA of 10.35 is 531.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Grand Pharmaceutical Group. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Debt-to-EBITDA is 10.35, which is 661% above median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.63, compared to a current price of €0.51 — trading 19.8% below its estimated fair value. The current Debt-to-EBITDA is 10.35, which is 661% above median its 10-year median of 1.36 and 531.1% above the Drug Manufacturers industry median of 1.64. Grand Pharmaceutical Group's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Debt-to-EBITDA is 10.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.51 is trading 19.8% below its estimated GF Value™ of €0.63.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
Debt-to-EBITDA: 10.35 (661% above median its 10-year median of 1.36)
GF Value™: €0.63 vs. price of €0.51 (19.8% below fair value)
Industry Position: 531.1% above the Drug Manufacturers median (#446 of 675)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
88GF Score
Get the complete analysis for FRA:MX6A
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
